Non Executive Chairman
Dan was founder, President and CEO of Rempex Pharmaceuticals, Inc., an antibiotic company that was sold to the Medicines Company. Previously Dan was President and CEO of Mpex Pharmaceuticals, Inc., a company that advanced an inhaled antibiotic for cystic fibrosis patients into Phase 3 clinical trials; the drug was acquired by Aptalis, Inc. in 2011. Dan has also held senior executive positions at a number of other biotechnology companies. He served as a Director and Chairman of the Audit Committee of Santarus, Inc. for 10 years until its acquisition by Salix, Inc. in 2014 for $2.7 billion. Dan holds the following external Board seats: Nabriva Therapeutics (Chairman, NASDAQ:NBRV), Atox Bio (Chairman), Cidara Therapeutics (NASDAQ: CDTX) and Arbutus Biopharma (NASDAQ: ABUS). He is also Chairman of Biocom, the life science industry association of California that represents more than 800 member companies.
Dan is a graduate of Stanford University (AB, Economics) and Harvard Business School (MBA).
Non Executive Director
Matthew is a partner at SR One in London.
Mr. Foy joined SR One’s London office in 2011. Previously he was a Vice President at Greenhill & Co, an M&A Investment Bank and Private Equity firm in New York. His portfolio companies include Asceneuron, AtoxBio, Progenitor, PsiOxus, Puridify and VHSquared.
Matthew studied Molecular Biology at The University of Oxford; Drug Discovery at UCL; Corporate Finance at The London Business School and holds various FSA & SEC qualifications
Kate is Managing Partner at SVLS and is based in London.
Kate currently serves or has served on the boards of companies in the UK, US, Ireland, Sweden and Germany. She has been responsible for past investments in Affinium, Alantos, Auxilium, Convergence, ESBATech, EUSA, Hexagen, Kinetix, KuDOS, Leukosite, MedNova, Micromet, Oncoethix, PowderMed, RespiVert and Vantia and current investments including Atopix, Autifony, Bicycle, Calchan, Kalvista, Karus, Kesios, Pulmocide, TopiVert and VHSquared. Kate has played an active role in setting up the new Dementia Discovery Fund (DDF) and serves on the DDF Investment Committee as well as the Investment Committees for all SV’s funds. Prior to joining SVLS, Kate worked in business development for Vertex Pharmaceuticals, a biotechnology company in Cambridge, MA and at Monitor Company, a strategy consulting firm. Kate has a first class degree in Biochemistry from Oxford University and graduated from Harvard Business School with an MBA (Baker Scholar).
Jeanne Bolger, MB BCh BAO, Vice President, Venture Investments, joined Johnson & Johnson Innovation – JJDC, Inc. (JJDC) in 2013. She is based in London, UK. Dr. Bolger has over 25 years of pharmaceutical industry experience in management roles across R&D, Commercial and Business Development (BD). She spent 11 years in Licensing and Acquisition (L&A), most recently as Global Head of Scientific Licensing for Johnson & Johnson’s Pharmaceutical business, having joined Johnson & Johnson in 2005 from the Business Development group at GlaxoSmithKline. In 2009, Dr. Bolger became Vice President, Alliance Management at Janssen Alzheimer Immunotherapy, working with Pfizer and Elan. Dr. Bolger received her medical degree from University College Dublin. She also holds diplomas in Child Health (NUI) and in Finance and Accounting (ACCA). She is a Fellow of the Royal Academy of Medicine of Ireland (RAMI). Dr. Bolger has served as the sole pharma industry representative on two Irish government taskforces seeking to enhance the commercialization of IP from Irish academic centres. She is a visiting lecturer on the MSc Pharmaceutical Medicine curriculum at Trinity College in Dublin, Ireland
Maina Bhaman is Director of Healthcare Investments at Imperial Innovations. Maina has led a number of investments in Imperial Innovations’ healthcare portfolio including recent investments into Psioxus Therapeutics and Cellmedica . Maina currently serves on the board of Autifony Therapeutics, Cell Medica, Ixico ,Psioxus Therapeutics and Topivert Pharma. Maina was also served on the board of Acrobot and Molecular Vision Ltd. Maina joined Innovations in 2006 and prior to that worked in the research and development team at Celltech (previously Oxford Glyco Sciences). Maina’s experience includes Chimeric Therapies, a cell therapy start-up based in Philadelphia and GeneMedicine, a gene therapy company based in Houston, Tx. Maina has a BSc from the University of Texas at Austin and an MBA from the Imperial Business School.
Stephen Knight joined F-Prime Capital in 2003 where he serves as President and Managing Partner. He has worked in the pharmaceutical and biotechnology industries for over 25 years and invests broadly across healthcare. Steve currently serves as Chairman of the Board of Directors for Forum Pharmaceuticals (formerly EnVivo Pharmaceuticals) and serves on the Board of Directors of Innovent Biologics, Proteostasis Therapeutics, Iora Health, Pulmocide, Semma Therapeutics and Denali Therapeutics. Steve previously served on the boards of several private and public health care companies including, Blueprint Medicines (NASDAQ: BPMC) FoldRx Pharmaceuticals (acquired by Pfizer), Ironwood Pharmaceuticals (NASDAQ: IRWD), NextWave Pharmaceuticals (acquired by Pfizer), and Respivert, Ltd (acquired by J&J).
Prior to joining F-Prime Capital, Steve held various senior management roles in private and public biotechnology and consulting companies. He also was a researcher at AT&T Bell Laboratories, the National Institutes of Health, and Yale University. He holds an M.D. from the Yale University School of Medicine, an M.B.A. from the Yale School of Organization and Management and received a B.S. in biology from Columbia University, graduating summa cum laude and Phi Beta Kappa.
Garth Rapeport is CEO of Pulmocide Ltd (http://pulmocide.com/), a drug discovery company working on the identification of new treatments for Invasive Aspergillosis and RSV and visiting Professor at the National Heart & Lung Institute, Imperial College School of Medicine in London.
Garth is a medical graduate who undertook post-graduate training in General Medicine and Clinical Pharmacology at the Universities of Glasgow and Oxford. He joined Pfizer Central Research in 1988 and was involved in the early development of range of new compounds. After moving to GSK he was head of the Respiratory Centre of Excellence for Drug Discovery (CEDD) leading to the development of new long acting inhaled therapies for COPD and asthma.
In 2006 he co-founded Respivert which was based at the Imperial College BioIncubator in London. Respivert was acquired by Centocor Ortho Biotech, a division of Johnson and Johnson in June 2010.
Pete is Pulmocide’s Chief Scientific Officer. The majority of Pete’s pharmaceutical industry career between 1980 and 2003 was spent at Glaxo PLC, GlaxoWellcome and GlaxoSmithKline with a focus on respiratory drug discovery and development. Pete co-foundedr Respivert with Garth Rapeport and colleagues in 2007. Following the acquisition in 2010 by Centocor Ortho Biotech, Pete was a member of the small team which licensed the appropriate Respivert intellectual property rights to Topivert Ltd, leading to the successful Series A funding of that company.